-
1
-
-
20244376625
-
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial
-
Antoni C, Kavanaugh A, Kirkham B, et al. 2005a. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial. Arthritis Rheum, 52:1227-36.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 1227-1236
-
-
Antoni, C.1
Kavanaugh, A.2
Kirkham, B.3
-
2
-
-
19044382942
-
Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial
-
Antoni C, Krueger GG, de Vlam K, et al. 2005b. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis, 64:1150-75.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1150-1175
-
-
Antoni, C.1
Krueger, G.G.2
de Vlam, K.3
-
3
-
-
0033546665
-
The lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralisation in MS: Results of a randomised. placebo controlled multicentre study
-
Arnason BGW 1999. The lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralisation in MS: results of a randomised. placebo controlled multicentre study. Neurology, 53:457-65.
-
(1999)
Neurology
, vol.53
, pp. 457-465
-
-
Arnason, B.G.W.1
-
4
-
-
33845660797
-
Individualized monitoring of drug bioavailability and immogenicity in rheumatoid arthritis patients treated with tumour necrosis factor alpha inhibitor infliximab
-
Bendtzen K, Geborek P, Svenson M et al. 2006. Individualized monitoring of drug bioavailability and immogenicity in rheumatoid arthritis patients treated with tumour necrosis factor alpha inhibitor infliximab. Arthritis Rhem, 54:3782-89.
-
(2006)
Arthritis Rhem
, vol.54
, pp. 3782-3789
-
-
Bendtzen, K.1
Geborek, P.2
Svenson, M.3
-
5
-
-
3042703125
-
Treatment of recalcitrant pustular psoriasis with infliximab: Effective reduction of chemokine expression
-
Benoit S, Toksoy A, Brocker EB et al. 2004. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol, 150:1009-12.
-
(2004)
Br J Dermatol
, vol.150
, pp. 1009-1012
-
-
Benoit, S.1
Toksoy, A.2
Brocker, E.B.3
-
6
-
-
17844386820
-
Remission and time of resolution of nail psoriasis during infliximab therapy
-
Bianchi L, Bergamin A, de Felice C, et al. 2005. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol, 52:736-7.
-
(2005)
J Am Acad Dermatol
, vol.52
, pp. 736-737
-
-
Bianchi, L.1
Bergamin, A.2
de Felice, C.3
-
7
-
-
33646696885
-
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
-
Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-95.
-
(2006)
JAMA
, vol.295
, pp. 2275-2295
-
-
Bongartz, T.1
Sutton, A.J.2
Sweeting, M.J.3
-
8
-
-
0036637636
-
Therapeutic Management of psoriasis
-
Bundu-Kamara S. 2002. Therapeutic Management of psoriasis Hospital Pharmacist 9:191-99.
-
(2002)
Hospital Pharmacist
, vol.9
, pp. 191-199
-
-
Bundu-Kamara, S.1
-
9
-
-
33744801949
-
Psoriasis: A general overview
-
Burd RM. 2006. Psoriasis: a general overview. Br J Hosp Med, 67:259-62.
-
(2006)
Br J Hosp Med
, vol.67
, pp. 259-262
-
-
Burd, R.M.1
-
10
-
-
61549106416
-
Immunological evidence for increasing reactivity to secreted Streptococcus pyogenes proteins in chronic plaque psoriasis: FC-13
-
Camp RDR, El-Rachkidy RG, Young HS, et al. 2006. Immunological evidence for increasing reactivity to secreted Streptococcus pyogenes proteins in chronic plaque psoriasis: FC-13. Br J Dermatol, 154(Suppl 1):5.
-
(2006)
Br J Dermatol
, vol.154
, Issue.SUPPL. 1
, pp. 5
-
-
Camp, R.D.R.1
El-Rachkidy, R.G.2
Young, H.S.3
-
11
-
-
34547774225
-
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis
-
Capon F, Di Meglio P, Szaub J, et al. 2007. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet, 122(2):201-6.
-
(2007)
Hum Genet
, vol.122
, Issue.2
, pp. 201-206
-
-
Capon, F.1
Di Meglio, P.2
Szaub, J.3
-
12
-
-
2542445474
-
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
-
Carlin CS, Feldman SR, Krueger JG, et al. 2004. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50:859-66.
-
(2004)
J Am Acad Dermatol
, vol.50
, pp. 859-866
-
-
Carlin, C.S.1
Feldman, S.R.2
Krueger, J.G.3
-
13
-
-
15744398663
-
Combining traditional agents and biologies for treatment of psoriasis
-
Cather J, Menter A. 2005. Combining traditional agents and biologies for treatment of psoriasis. Semin Cut Med Surg, 24:37-45.
-
(2005)
Semin Cut Med Surg
, vol.24
, pp. 37-45
-
-
Cather, J.1
Menter, A.2
-
14
-
-
61549130092
-
-
Centocor Inc. 2006. Remicade (infliximab) package insert: Chicago, II, USA available at
-
Centocor Inc. 2006. Remicade (infliximab) package insert: Chicago, II, USA available at www.gene.com/gene/products/information/pdf/ raptivaprescribing.pdf
-
-
-
-
16
-
-
47249159958
-
Psoriatic skin lesions induced by tumour necrosis factor antagonist therapy: A literature review and potential mechanisms of action
-
Collamer A, Guerrero KT, Henning JS, et al. 2008. Psoriatic skin lesions induced by tumour necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Care and Research, 57:996-1001.
-
(2008)
Arthritis Care and Research
, vol.57
, pp. 996-1001
-
-
Collamer, A.1
Guerrero, K.T.2
Henning, J.S.3
-
17
-
-
0035072326
-
Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci
-
Cookson WO. Ubhi B. Lawrence R et al. 2001. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nature Genetics, 27(4):372-3.
-
(2001)
Nature Genetics
, vol.27
, Issue.4
, pp. 372-373
-
-
Cookson, W.O.1
Ubhi, B.2
Lawrence, R.3
-
18
-
-
33750797800
-
-
Dixon W, Silman A. 2006. Is there an association between anti-TNF antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta analysis by Bongartz et al. Arthritis Res Ther, 8:11.
-
Dixon W, Silman A. 2006. Is there an association between anti-TNF antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta analysis by Bongartz et al. Arthritis Res Ther, 8:11.
-
-
-
-
19
-
-
34848839939
-
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)
-
Dixon WG, Symmons DP, Lunt M, et al. 2007. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Arthritis Rheum, 56:2896-904.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 2896-2904
-
-
Dixon, W.G.1
Symmons, D.P.2
Lunt, M.3
-
20
-
-
33745544337
-
PSORS 1: Linking genetics and immunology
-
Elder JT. 2006. PSORS 1: linking genetics and immunology. J Invest Dermatol, 126:1205-6.
-
(2006)
J Invest Dermatol
, vol.126
, pp. 1205-1206
-
-
Elder, J.T.1
-
22
-
-
0000219334
-
Human ant-chimaeric antibody levels correlate with a lack of response and infusion reactions following infliximab therapy
-
abstract 364
-
Farrel RJ, Alsahli M, Falchuk KR, et al. 2001. Human ant-chimaeric antibody levels correlate with a lack of response and infusion reactions following infliximab therapy. Gastroenterology, 120(Suppl 1):A69 abstract 364.
-
(2001)
Gastroenterology
, vol.120
, Issue.SUPPL. 1
-
-
Farrel, R.J.1
Alsahli, M.2
Falchuk, K.R.3
-
23
-
-
14244250511
-
Psoriasis assessment tools in clinical practice
-
Feldman SR, Krueger GG. 2005. Psoriasis assessment tools in clinical practice. Ann Rheum Dis, 64(Suppl ii):65-8.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.SUPPL. II
, pp. 65-68
-
-
Feldman, S.R.1
Krueger, G.G.2
-
24
-
-
21044440425
-
Infliximab results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial
-
Feldman SR, Gordon KB, Bala M, et al. 2005. Infliximab results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. J Am Acad Dermatol, 152:954-60.
-
(2005)
J Am Acad Dermatol
, vol.152
, pp. 954-960
-
-
Feldman, S.R.1
Gordon, K.B.2
Bala, M.3
-
25
-
-
18944404879
-
Current severe psoriasis and the rule of tens
-
Finlay AY 2005. Current severe psoriasis and the rule of tens. Br J Dermatol, 152:861-7.
-
(2005)
Br J Dermatol
, vol.152
, pp. 861-867
-
-
Finlay, A.Y.1
-
26
-
-
29144466801
-
Prevalence and treatment of psoriasis in the United Kingdom: A population - base study
-
Gelfland JM, Weinstein R, Porter SB, et al. 2005. Prevalence and treatment of psoriasis in the United Kingdom: a population - base study. Arch Dermatol, 141:1537-41.
-
(2005)
Arch Dermatol
, vol.141
, pp. 1537-1541
-
-
Gelfland, J.M.1
Weinstein, R.2
Porter, S.B.3
-
27
-
-
33749613119
-
Risk of myocardial infarction in patients with psoriasis
-
Gelfand JM, Neimann AL, Shin DB, et al. 2006. Risk of myocardial infarction in patients with psoriasis. JAMA, 296:1735-41.
-
(2006)
JAMA
, vol.296
, pp. 1735-1741
-
-
Gelfand, J.M.1
Neimann, A.L.2
Shin, D.B.3
-
28
-
-
0030826483
-
T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice
-
Gilhar A, David M, Ullman T, et al. 1997. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol, 109:283-8.
-
(1997)
J Invest Dermatol
, vol.109
, pp. 283-288
-
-
Gilhar, A.1
David, M.2
Ullman, T.3
-
29
-
-
39049173409
-
Anti-tumour necrosis factor alpha therapy increases bodt weight in patients with chronic plaque psoriasis: A retrospective cohort study
-
Gisondi P, Cotena C, tessari G, et al. 2007. Anti-tumour necrosis factor alpha therapy increases bodt weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol, 22:341-4.
-
(2007)
J Eur Acad Dermatol
, vol.22
, pp. 341-344
-
-
Gisondi, P.1
Cotena, C.2
tessari, G.3
-
30
-
-
14244260176
-
Psoriatic arthritis: Epidemiology, clinical features, course and outcome
-
Gladman D, Antoni C, Mease P, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis, 64(Suppl 1):14-7.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.SUPPL. 1
, pp. 14-17
-
-
Gladman, D.1
Antoni, C.2
Mease, P.3
-
31
-
-
4644327125
-
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomised double-blind, placebo-controlled trial
-
Gottlieb AB, Evans R, Li S, et al. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomised double-blind, placebo-controlled trial. J Am Acad Dermatol, 51:534-42.
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 534-542
-
-
Gottlieb, A.B.1
Evans, R.2
Li, S.3
-
32
-
-
0032806844
-
Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis?
-
Gudmundsdottir AS, Sigmundsdotir H, Sigurgeirsson B, et al. 1999. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Dermatol. 117:580-6.
-
(1999)
Clin Exp Dermatol
, vol.117
, pp. 580-586
-
-
Gudmundsdottir, A.S.1
Sigmundsdotir, H.2
Sigurgeirsson, B.3
-
33
-
-
30144436177
-
Anti-infiximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response
-
Haraoui B, Cameron L, Ouellet M, et al. 2006. Anti-infiximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol, 33:31-6.
-
(2006)
J Rheumatol
, vol.33
, pp. 31-36
-
-
Haraoui, B.1
Cameron, L.2
Ouellet, M.3
-
34
-
-
19644364586
-
The benefit/risk profile of TNT - blocking agents: Findings of a concensus panel
-
Hochberg MC, Lebwohl MG, Plevy, et al. 2005. The benefit/risk profile of TNT - blocking agents: findings of a concensus panel. Semin Arthritis Rheum, 34:819-36.
-
(2005)
Semin Arthritis Rheum
, vol.34
, pp. 819-836
-
-
Hochberg, M.C.1
Lebwohl, M.G.2
Plevy3
-
35
-
-
33746972770
-
Pregnancy outcome in women who were exposed to anti-tumour necrosis factor agents: Results from a national population register
-
Hyrich KL, Symmons DPM, Watson KD, et al. 2006. Pregnancy outcome in women who were exposed to anti-tumour necrosis factor agents: results from a national population register. Arthritis Rheum, 54:2701-8.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2701-2708
-
-
Hyrich, K.L.1
Symmons, D.P.M.2
Watson, K.D.3
-
36
-
-
34147204834
-
Infliximab maintains a higher degree of clinical response through 1 year of treatment: Results from the IMPACT 2 trial
-
Kavanaugh A, Krueger GG, Bender A, et al. 2007. Infliximab maintains a higher degree of clinical response through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis, 66:498-505.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 498-505
-
-
Kavanaugh, A.1
Krueger, G.G.2
Bender, A.3
-
37
-
-
0036145337
-
The immunological basis for the treatment of psoriasis with new biological agents
-
Krueger JG. 2002. The immunological basis for the treatment of psoriasis with new biological agents. J Am Acad Dermatol, 46:1-23.
-
(2002)
J Am Acad Dermatol
, vol.46
, pp. 1-23
-
-
Krueger, J.G.1
-
38
-
-
0037672879
-
Case reports of heart failure after therapy with tumour necrosis factor antagonist
-
Kwon HJ, Cote TR, Cuffe MS, et al. 2003. Case reports of heart failure after therapy with tumour necrosis factor antagonist. Ann Intern Med, 138:807-11.
-
(2003)
Ann Intern Med
, vol.138
, pp. 807-811
-
-
Kwon, H.J.1
Cote, T.R.2
Cuffe, M.S.3
-
39
-
-
0037420518
-
Psoriasis
-
Lebowohl M. 2003. Psoriasis. Lancet, 361:1197-204.
-
(2003)
Lancet
, vol.361
, pp. 1197-1204
-
-
Lebowohl, M.1
-
40
-
-
30444432567
-
Obesity, smoking and psoriasis
-
Lebowohl M, Callen JP. 2006. Obesity, smoking and psoriasis. JAMA, 295:208-10.
-
(2006)
JAMA
, vol.295
, pp. 208-210
-
-
Lebowohl, M.1
Callen, J.P.2
-
41
-
-
49749131222
-
Review and expert opinion on the prevention and treatment of infliximab-related infusion reactions
-
Lecluse LLA, Piskin G, Mekkes JR, et al. 2008. Review and expert opinion on the prevention and treatment of infliximab-related infusion reactions. Br J Dermatol, 159:527-36.
-
(2008)
Br J Dermatol
, vol.159
, pp. 527-536
-
-
Lecluse, L.L.A.1
Piskin, G.2
Mekkes, J.R.3
-
42
-
-
1842450793
-
10 years experience of the Dermatology Life Quality index (DLQI)
-
Lewis V, Finlay AY. 2004. 10 years experience of the Dermatology Life Quality index (DLQI) J Invest Dermatol Symp Proc, 9:169-8.
-
(2004)
J Invest Dermatol Symp Proc
, vol.9
, pp. 169-178
-
-
Lewis, V.1
Finlay, A.Y.2
-
43
-
-
33746443001
-
Life threatening pustular and eythrodermic psoriasis responding to infliximab
-
Lewis TG, Tuchinda C, Lim HW, et al. 2006. Life threatening pustular and eythrodermic psoriasis responding to infliximab. J Drugs Dermatol, 5:546-8.
-
(2006)
J Drugs Dermatol
, vol.5
, pp. 546-548
-
-
Lewis, T.G.1
Tuchinda, C.2
Lim, H.W.3
-
45
-
-
33846592386
-
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
-
Mackkey AC, Green L, Liang LC, et al. 2007. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 44:265-7.
-
(2007)
J Pediatr Gastroenterol Nutr
, vol.44
, pp. 265-267
-
-
Mackkey, A.C.1
Green, L.2
Liang, L.C.3
-
46
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis
-
Maini RN, Breedveld FC, Kalden JR, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum, 41:1552-63.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
-
47
-
-
1842663219
-
Increased risk for cardiovascular mortality in psoriasis inpatients but not outpatients
-
Mallbris L, Arke O, Granath F, et al. 2004. Increased risk for cardiovascular mortality in psoriasis inpatients but not outpatients. Eur J Epidemiol, 19:225-30.
-
(2004)
Eur J Epidemiol
, vol.19
, pp. 225-230
-
-
Mallbris, L.1
Arke, O.2
Granath, F.3
-
48
-
-
15044361734
-
Psoriasis phenotype at disease onset: Clinical characterisation of 400 adult cases
-
Mallbris L, Larsson P, Bergqvist S, et al. 2005. Psoriasis phenotype at disease onset: clinical characterisation of 400 adult cases. J Invest Dermatol, 124:499-504.
-
(2005)
J Invest Dermatol
, vol.124
, pp. 499-504
-
-
Mallbris, L.1
Larsson, P.2
Bergqvist, S.3
-
50
-
-
11144277873
-
Diagnosis and treatment of psoriatic arthritis
-
Mease P, Goffe B. 2005. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol, 52:1-19.
-
(2005)
J Am Acad Dermatol
, vol.52
, pp. 1-19
-
-
Mease, P.1
Goffe, B.2
-
51
-
-
14244269341
-
Psoriatic arthritis assessment tools in clinical trials
-
Mease PJ, Antoni CE, Gladman DD et al. 2005. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis, 64:ii49-ii54.
-
(2005)
Ann Rheum Dis
, vol.64
-
-
Mease, P.J.1
Antoni, C.E.2
Gladman, D.D.3
-
52
-
-
61549105129
-
Quality of life issues in psoriasis and psoriatic arthritis:Outcome measure and therapies from a dermatological perspective
-
Mease PJ, Menter A. 2006. Quality of life issues in psoriasis and psoriatic arthritis:Outcome measure and therapies from a dermatological perspective. J Am Acad Dermatol, 50:859-66.
-
(2006)
J Am Acad Dermatol
, vol.50
, pp. 859-866
-
-
Mease, P.J.1
Menter, A.2
-
53
-
-
1342346479
-
Successfal treatment of pediatric psoriasis with infliximab
-
Menter M, Alan MD, Cush JM, et al. 2004. Successfal treatment of pediatric psoriasis with infliximab. Paed Dermatol, 21:87-8.
-
(2004)
Paed Dermatol
, vol.21
, pp. 87-88
-
-
Menter, M.1
Alan, M.D.2
Cush, J.M.3
-
54
-
-
33845692734
-
-
Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomised comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-severe plaque psoriasis. J Am Acad Dermatol, 56:31.e1-15.
-
Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomised comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-severe plaque psoriasis. J Am Acad Dermatol, 56:31.e1-15.
-
-
-
-
55
-
-
0035674613
-
Demyelination occurring during anti-tumour necrosis factor alpha for inflammatory arthritidies
-
Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring during anti-tumour necrosis factor alpha for inflammatory arthritidies. Arthritis Rheum, 44:2862-9.
-
(2001)
Arthritis Rheum
, vol.44
, pp. 2862-2869
-
-
Mohan, N.1
Edwards, E.T.2
Cupps, T.R.3
-
57
-
-
39949085766
-
Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque type psoriasis: Report on five cases
-
Mossner R, Thaci D, Mohr J, et al. 2008. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque type psoriasis: report on five cases. Arch Dermatol Res, 30:101-5.
-
(2008)
Arch Dermatol Res
, vol.30
, pp. 101-105
-
-
Mossner, R.1
Thaci, D.2
Mohr, J.3
-
58
-
-
22144490239
-
Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case control study
-
Naldi L, Chatenoud L, Linder D, et al. 2005. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case control study. J Inves Dermatol, 125:61-7.
-
(2005)
J Inves Dermatol
, vol.125
, pp. 61-67
-
-
Naldi, L.1
Chatenoud, L.2
Linder, D.3
-
59
-
-
61549130736
-
Infliximab for the treatment of adults with psoriasis- Final Scope
-
technology appraisal [online, URL
-
NICE. 2006. Infliximab for the treatment of adults with psoriasis- Final Scope. NICE single technology appraisal [online]. URL: www.nice.org.uk/ TA134.
-
(2006)
NICE single
-
-
-
60
-
-
0025831330
-
The cytokine network in psoriasis
-
Nickoloff BJ. 1999. The cytokine network in psoriasis. Arch Dermatol, 127:871-84.
-
(1999)
Arch Dermatol
, vol.127
, pp. 871-884
-
-
Nickoloff, B.J.1
-
62
-
-
0032761861
-
Excess mortality related to alcohol and smoking among hospital treated patients with psoriasis
-
Poikolainen K, Karvonen J, Pukkala E. 1999. Excess mortality related to alcohol and smoking among hospital treated patients with psoriasis. Arch Dermatol, 135:1490-3.
-
(1999)
Arch Dermatol
, vol.135
, pp. 1490-1493
-
-
Poikolainen, K.1
Karvonen, J.2
Pukkala, E.3
-
63
-
-
33846185076
-
A follow up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: Evidence for efficacy and high incidence of biological immunity
-
Poulalhon N, Begon E Lebbe C, et al. 2007. A follow up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological immunity. Br J Dermatol, 156;329-36.
-
(2007)
Br J Dermatol
, vol.156
, pp. 329-336
-
-
Poulalhon, N.1
Begon, E.2
Lebbe, C.3
-
64
-
-
0032872277
-
Psoriasis causes as much disability as other major medical diseases
-
Rapp SR, Feldman SR, Exum ML, et al. 1999. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol, 41:401-7.
-
(1999)
J Am Acad Dermatol
, vol.41
, pp. 401-407
-
-
Rapp, S.R.1
Feldman, S.R.2
Exum, M.L.3
-
65
-
-
38449110911
-
Brief communication: Characteristics of spontaneous cases of tuberculosis associated with Infliximab
-
Raval A, Akhavan-Toyserkani G, Brinker A et al. 2007. Brief communication: characteristics of spontaneous cases of tuberculosis associated with Infliximab. Ann Int Med, 147;699-702.
-
(2007)
Ann Int Med
, vol.147
, pp. 699-702
-
-
Raval, A.1
Akhavan-Toyserkani, G.2
Brinker, A.3
-
66
-
-
26644433889
-
Infliximab induction and maintenance for moderate-to-severe psoriasis: A phase III, multi centre, double-blind trial
-
Reich K, Nestle FO, Papp, K, et al. 2005. Infliximab induction and maintenance for moderate-to-severe psoriasis: a phase III, multi centre, double-blind trial. Lancet, 366:1367-74.
-
(2005)
Lancet
, vol.366
, pp. 1367-1374
-
-
Reich, K.1
Nestle, F.O.2
Papp, K.3
-
67
-
-
38349097035
-
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
-
Rich P, Griffiths CE, Reich K, et al. 2008. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol, 58:224-31.
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 224-231
-
-
Rich, P.1
Griffiths, C.E.2
Reich, K.3
-
68
-
-
47549099185
-
Evaluation of the efficacy and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, open-label study
-
Rigopoulos D, Gregoriou S, Stratigos A, et al. 2008. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol, 159:453-6.
-
(2008)
Br J Dermatol
, vol.159
, pp. 453-456
-
-
Rigopoulos, D.1
Gregoriou, S.2
Stratigos, A.3
-
69
-
-
34250662578
-
Successful treatment of severe psoriatic arthritis with infliximab in an 11 year old child suffering from linear psoriasis along the lines of Blaschko
-
Rott S, Kuster RM, Mrowietz U. 2007. Successful treatment of severe psoriatic arthritis with infliximab in an 11 year old child suffering from linear psoriasis along the lines of Blaschko. Br J Dermatol, 157:191-2.
-
(2007)
Br J Dermatol
, vol.157
, pp. 191-192
-
-
Rott, S.1
Kuster, R.M.2
Mrowietz, U.3
-
70
-
-
51349119641
-
Long-term management of generalized ustular psoriasis with infliximab: Case series
-
Routhouska SB, Sheth PB, Korman NJ. 2008. Long-term management of generalized ustular psoriasis with infliximab: case series. J Cut Med Surg, 12:184-8.
-
(2008)
J Cut Med Surg
, vol.12
, pp. 184-188
-
-
Routhouska, S.B.1
Sheth, P.B.2
Korman, N.J.3
-
71
-
-
7044264854
-
A comprehensive review and evaluation of the side effects of tumour necrosis factor alpha blockers, etanercept, infliximab and adalimumab
-
Scheinfeld N. 2004. A comprehensive review and evaluation of the side effects of tumour necrosis factor alpha blockers, etanercept, infliximab and adalimumab. Dermatol Treat, 15:280-94.
-
(2004)
Dermatol Treat
, vol.15
, pp. 280-294
-
-
Scheinfeld, N.1
-
72
-
-
0022253623
-
Psoriasis of the nail
-
Scher RK. 1985. Psoriasis of the nail. Dermatol Clin, 3:387-94.
-
(1985)
Dermatol Clin
, vol.3
, pp. 387-394
-
-
Scher, R.K.1
-
73
-
-
1542402063
-
Recalcitrant, generalized pustular psoriasis: Rapid and lasting therapeutic response to anti tumour necrosis factor-alpha antibody (infliximab)
-
Schinick K, Grabbe J. 2004. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to anti tumour necrosis factor-alpha antibody (infliximab). Br J Dermatol, 150:367.
-
(2004)
Br J Dermatol
, vol.150
, pp. 367
-
-
Schinick, K.1
Grabbe, J.2
-
74
-
-
61549138557
-
-
Scottish Medicines Consortium guidance on infliximab 100 mg powder for intravenous infusion (Remicade) No
-
Scottish Medicines Consortium guidance on infliximab 100 mg powder for intravenous infusion (Remicade) No (318/06) 2007.
-
(2007)
, vol.318
, Issue.6
-
-
-
75
-
-
34548027771
-
Obesity, waist circurnference, weight change and the risk of psoriasis in women
-
Setty AR, Curhan G, Choi HK. 2007. Obesity, waist circurnference, weight change and the risk of psoriasis in women. Arch Intern Med, 167:1670-5.
-
(2007)
Arch Intern Med
, vol.167
, pp. 1670-1675
-
-
Setty, A.R.1
Curhan, G.2
Choi, H.K.3
-
76
-
-
24344471811
-
British Association of Dermatologists guideline for the use of biological interventions in psoriasis
-
Smith CH, Anstey AV, Barker, et al. 2005. British Association of Dermatologists guideline for the use of biological interventions in psoriasis. Br J Dermalol, 153:486-97.
-
(2005)
Br J Dermalol
, vol.153
, pp. 486-497
-
-
Smith, C.H.1
Anstey, A.V.2
Barker3
-
77
-
-
33747597605
-
Psoriasis and its management
-
Smith CH, Barker JN. 2006. Psoriasis and its management. BMJ, 333:380-4.
-
(2006)
BMJ
, vol.333
, pp. 380-384
-
-
Smith, C.H.1
Barker, J.N.2
-
78
-
-
34548590671
-
Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis
-
Takahashi MD, Castro LG, Romiti R. 2007. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol, 157:828-31.
-
(2007)
Br J Dermatol
, vol.157
, pp. 828-831
-
-
Takahashi, M.D.1
Castro, L.G.2
Romiti, R.3
-
79
-
-
0026501836
-
The role of streptococcal infection in the initiation of guttate psoriasis
-
Telfer NR, Chalmers RJ, Whale K, et al. 1992. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol, 128:39-42.
-
(1992)
Arch Dermatol
, vol.128
, pp. 39-42
-
-
Telfer, N.R.1
Chalmers, R.J.2
Whale, K.3
-
80
-
-
24144450014
-
Successful treatment of Von Zumbush pustular psoriasis with infliximab
-
Trent JT, Kerdel FA. 2004. Successful treatment of Von Zumbush pustular psoriasis with infliximab. J Cut Med Surg, 8:224-8.
-
(2004)
J Cut Med Surg
, vol.8
, pp. 224-228
-
-
Trent, J.T.1
Kerdel, F.A.2
-
81
-
-
0036188666
-
-
Uyanik BS, Ari Z Omur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. 2002. Clin Chem Lab Med, 40:65-8.
-
Uyanik BS, Ari Z Omur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. 2002. Clin Chem Lab Med, 40:65-8.
-
-
-
-
82
-
-
0031014382
-
Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross react with keratin?
-
Valdimarsson H, Sigmundsdottir H, Jonsdottir I. 1997. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross react with keratin? Clin Exp Dermatol, 107(Supp 1):21-4.
-
(1997)
Clin Exp Dermatol
, vol.107
, Issue.SUPP 1
, pp. 21-24
-
-
Valdimarsson, H.1
Sigmundsdottir, H.2
Jonsdottir, I.3
-
83
-
-
61549111385
-
Biologic agents offer hope for psoriasis. Business briefing: European
-
Van de Kerkhof P. 2003. Biologic agents offer hope for psoriasis. Business briefing: European Pharmacotherapy. p 124-8.
-
(2003)
Pharmacotherapy
, pp. 124-128
-
-
Van de Kerkhof, P.1
-
84
-
-
38549131372
-
Infliximab in recalcitrant generalised pustular arthropathic psoriasis
-
Vieira Serrao V, Martins A, Lopes MJ. 2008. Infliximab in recalcitrant generalised pustular arthropathic psoriasis. Eur J Dermatol, 18:71-2.
-
(2008)
Eur J Dermatol
, vol.18
, pp. 71-72
-
-
Vieira Serrao, V.1
Martins, A.2
Lopes, M.J.3
-
85
-
-
33749255411
-
Sequential use of infliximab and etanercept in generalized pustular psoriasis
-
Weisenseel P, Prinz JC. 2006. Sequential use of infliximab and etanercept in generalized pustular psoriasis Cutis, 78:197-9.
-
(2006)
Cutis
, vol.78
, pp. 197-199
-
-
Weisenseel, P.1
Prinz, J.C.2
-
86
-
-
33644931095
-
Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
-
Wolbink GJ, Vis M, Lems W, et al. 2006. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum, 54:711-5.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 711-715
-
-
Wolbink, G.J.1
Vis, M.2
Lems, W.3
-
87
-
-
37549005087
-
Tumour necrosis factor alpha inhibitor induced psoriasis or psoriasiform. exanthemata: First 120 cases from the literature including a series of six new patients
-
Wollina U, Hansel G, Koch A, et al. 2008. Tumour necrosis factor alpha inhibitor induced psoriasis or psoriasiform. exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol, 9:1-14.
-
(2008)
Am J Clin Dermatol
, vol.9
, pp. 1-14
-
-
Wollina, U.1
Hansel, G.2
Koch, A.3
|